France (FR)

A randomized phase II trial of ipilimumab and nivolumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNNIFORECAST) (2022) Ahrens M, Escudier B, Haanen J, Gross-Goupil M, Boleti E, Gravis G, Grimm MO, et al. Conference contribution Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution Trial in Progress: eine multizentrische Open-label Phase IB/ II Studie zur Bestimmung der Dosierung und Sicherheit von Asciminib bei padiatrischen Patienten mit chronischer myeloischer Leukamie in der chronischen Phase (ASC4kids) (2022) Metzler M, Escherich G, Reinhardt D, Kapoor S, Hoch M, Descamps L, Bayar MA, et al. Conference contribution Complementary Medicine and Nursing in Oncology Development of evidence-based, symptom-related topic guidelines for interprofessional counseling of tumor patients (2022) Kroeger B, Kaschdailewitsch E, Behzad A, Schmitt A, Lohmueller L, Valentini J, Noack B, et al. Conference contribution Viscoelastic properties of suspended cells measured with shear flow deformation cytometry (2022) Gerum R, Mirzahossein E, Eroles M, Elsterer J, Mainka A, Bauer A, Sonntag S, et al. Journal article Pathway to assess severe primary IGF-1 deficiency diagnosis in a real-life setting: data from the Global Increlex (R) Registry (2022) Bang P, Polak M, Bossowski A, De Schepper J, Sert C, Perrot V, Wölfle J Conference contribution Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, et al. Journal article Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases (2022) Zarbl J, Eimer E, Gigg C, Bendzuck G, Korinth M, Elling-Audersch C, Kleyer A, et al. Journal article Which patients should receive adjuvant treatment - an analysis of stage IIA-IIIA patients of the CMMR (2022) Leiter-Stoppke U, Keim U, Amaral T, Forschner A, Berking C, Gesierich A, Gutzmer R, et al. Conference contribution Assessment of the Genetic Spectrum of Uncombable Hair Syndrome in a Cohort of 107 Individuals (2022) Basmanav FB, Cesarato N, Kumar S, Borisov O, Kokordelis P, Ralser DJ, Wehner M, et al. Journal article